Tag Archives: Edward White

H.C. Wainwright Keeps Their Buy Rating on Clovis Oncology (CLVS)

H.C. Wainwright analyst Edward White reiterated a Buy rating on Clovis Oncology (CLVS – Research Report) today and set a price target of $237. The company’s shares closed on Friday at $23.48. According to TipRanks.com, White is a 5-star analyst

GlycoMimetics (GLYC) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Edward White maintained a Buy rating on GlycoMimetics (GLYC – Research Report) today and set a price target of $23. The company’s shares opened today at $12.82. White wrote: “We base our $23 price target on probability-adjusted

H.C. Wainwright Maintains a Buy Rating on TG Therapeutics (TGTX)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $20. The company’s shares opened today at $8.17. White said: “Our $20 price target

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Acceleron Pharma (NASDAQ: XLRN) and Pacira Pharmaceuticals (NASDAQ: PCRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Acceleron Pharma (XLRN – Research Report) and Pacira Pharmaceuticals (PCRX – Research Report). Acceleron Pharma (XLRN) In a report released today, Edward White from H.C.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Karyopharm Therapeutics (NASDAQ: KPTI), Strongbridge Biopharma Plc (NASDAQ: SBBP) and Jazz Pharmaceuticals (NASDAQ: JAZZ)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Karyopharm Therapeutics (KPTI – Research Report), Strongbridge Biopharma Plc (SBBP – Research Report) and Jazz Pharmaceuticals (JAZZ – Research Report). Karyopharm Therapeutics (KPTI)

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX), Irhythm Technologies (NASDAQ: IRTC) and Cytokinetics Inc (NASDAQ: CYTK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TG Therapeutics (TGTX – Research Report), Irhythm Technologies (IRTC – Research Report) and Cytokinetics Inc (CYTK – Research Report). TG Therapeutics (TGTX) In